Catálogo de publicaciones - revistas

<jats:title>Abstract</jats:title><jats:sec><jats:title>Aim</jats:title><jats:p>People with diabetes are at an increased risk of developing depression and other psychological disorders. However, little is known about the prevalence, correlates or care pathways in countries other than the <jats:styled-content style="fixed-case">UK</jats:styled-content> and the <jats:styled-content style="fixed-case">USA</jats:styled-content>. A new study, the International Prevalence and Treatment of Diabetes and Depression Study (<jats:styled-content style="fixed-case">INTERPRET</jats:styled-content>–<jats:styled-content style="fixed-case">DD</jats:styled-content>) aims to address this dearth of knowledge and identify optimal pathways to care across the globe.</jats:p></jats:sec><jats:sec><jats:title>Method</jats:title><jats:p><jats:styled-content style="fixed-case">INTERPRET</jats:styled-content>–<jats:styled-content style="fixed-case">DD</jats:styled-content> is a 2‐year longitudinal study, taking place in 16 countries’ diabetes outpatients’ facilities, investigating the recognition and management of depressive disorders in people with Type 2 diabetes. Clinical interviews are used to diagnose depression, with clinical and other data obtained from medical records and through patient interviews. Pathways to care and the impact of treatment for previously unrecognized (undocumented) depression on clinical outcomes and emotional well‐being are being investigated.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Initial evidence indicates that a range of pathways to care exist, with few of them based on available recommendations for treatment. Pilot data indicates that the instruments we are using to measure both the symptoms and clinical diagnosis of depression are acceptable in our study population and easy to use.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Our study will increase the understanding of the impact of comorbid diabetes and depression and identify the most appropriate (country‐specific) pathways via which patients receive their care. It addresses an important public health problem and leads to recommendations for best practice relevant to the different participating centres with regard to the identification and treatment of people with comorbid diabetes and depression.</jats:p></jats:sec>

<jats:title>Abstract</jats:title><jats:sec><jats:title>Aims</jats:title><jats:p>To assess the prevalence and management of depressive disorders in people with Type 2 diabetes in different countries.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>People with diabetes aged 18–65 years and treated in outpatient settings were recruited in 14 countries and underwent a psychiatric interview. Participants completed the Patient Health Questionnaire and the Problem Areas in Diabetes scale. Demographic and medical record data were collected.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>A total of 2783 people with Type 2 diabetes (45.3% men, mean duration of diabetes 8.8 years) participated. Overall, 10.6% were diagnosed with current major depressive disorder and 17.0% reported moderate to severe levels of depressive symptomatology (Patient Health Questionnaire scores &gt;9). Multivariable analyses showed that, after controlling for country, current major depressive disorder was significantly associated with gender (women) (<jats:italic>P</jats:italic>&lt;0.0001), a lower level of education (<jats:italic>P</jats:italic>&lt;0.05), doing less exercise (<jats:italic>P</jats:italic>&lt;0.01), higher levels of diabetes distress (<jats:italic>P</jats:italic>&lt;0.0001) and a previous diagnosis of major depressive disorder (<jats:italic>P</jats:italic>&lt;0.0001). The proportion of those with either current major depressive disorder or moderate to severe levels of depressive symptomatology who had a diagnosis or any treatment for their depression recorded in their medical records was extremely low and non‐existent in many countries (0–29.6%).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Our international study, the largest of this type ever undertaken, shows that people with diabetes frequently have depressive disorders and also significant levels of depressive symptoms. Our findings indicate that the identification and appropriate care for psychological and psychiatric problems is not the norm and suggest a lack of the comprehensive approach to diabetes management that is needed to improve clinical outcomes.</jats:p></jats:sec>